Methods. We used data from the 2009 cycle of the Medical Monitoring Project (MMP), a cross-sectional survey of a representative sample of US HIV-positive adults in care. We included women diagnosed > 1 year before interview if aged < 45 years at diagnosis and compared women with and without ≥ 1 pregnancy after HIV diagnosis. We examined the association of pregnancy with years since HIV diagnosis and the following exposures during the 12 months preceding MMP survey: sexually transmitted disease (STD) screening, HIV/STD prevention conversations with providers, prescription of antiretroviral therapy (ART), documentation of viral suppression (≤ 200 copies/mL), and unprotected sex with a man of unknown or HIV-negative status. We computed unadjusted and adjusted prevalence ratios (APR) and 95% confidence intervals (CI) using logistic regression.
Results. Data were available for 939 respondents representing 94,718 HIV-positive women; 4.8% were currently pregnant or had been pregnant in the previous 12 months. Median age at diagnosis was 30.5 years; 60.1% were non-Hispanic black. Of respondents, 27% were screened for chlamydia or gonorrhea; 51% had HIV/STD prevention conversations with providers; 87% were prescribed ART, 66% achieved viral suppression; 16.9% reported unprotected sex with an HIV-negative man or man of unknown HIV status. Overall, 29.7% of women reported ≥ 1 pregnancy after diagnosis. Having ≥ 1 pregnancy since HIV diagnosis was more likely among women who were ≤ 19 years at HIV diagnosis (APR 7.8 CI 4.5 -13.4); interviewed 5 -9 years since their HIV diagnosis (APR 1.4 CI 1.03 -1.9); were virologically suppressed (APR 1.4 CI 1.2 -1.7); and reported unprotected sex with a male of unknown or HIV-negative status (APR 1.5 CI 1.1 -2.0).
Conclusion. These data suggest that interventions are needed to: 1) optimize viral suppression; 2) increase HIV/STD prevention conversations; and 3) incorporate reproductive health discussions as part of routine care for HIV-infected women.
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